Patents by Inventor Wenteng Chen

Wenteng Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11946476
    Abstract: The present disclosure provides a compressor rotor, a compressor and a refrigerant circulation system. The compressor rotor includes: a motor rotor including a plurality of rotor sections, a locking rod, a compression unit rotating part and a locking member. The rotor sections are fixedly connected in an axial direction and are provided with an axial through hole and the locking rod penetrates through the axial through hole. The compression unit rotating part is located at the end part of the motor rotor and is connected to the locking rod. The locking member is configured to lock the compression unit rotating part on the locking rod. The locking rod, the compression unit rotating part and the locking member form a pressing structure which applies a pressure toward an axial inner side to the motor rotor.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: April 2, 2024
    Assignee: Gree Electric Appliances, Inc. of Zhuhai
    Inventors: Hua Liu, Zhiping Zhang, Yuhui Chen, Ruixing Zhong, Hongbo Li, Wenteng Ye, Jingli Qi
  • Publication number: 20230257411
    Abstract: A synthesis method for selamectin was developed, where doramectin is oxidized by manganese dioxide, oximated and de-sugared in one-step by an aqueous solution of hydroxylamine hydrochloride, and then selectively reduced in the presence of Wilkinson's catalyst and hydrogen to obtain selamectin. Doramectin is oxidized to a carbonyl group firstly, so that the generation of impurities during the subsequent reaction is reduced; t-butyl alcohol with a larger steric hindrance is used as a solvent, so that transesterification impurities are avoided; the hydrogenation is implemented in the final step, and the crude product is recrystallized before the hydrogenation reaction, so that the cost is greatly reduced. The method of the present application with an overall yield of 57%. The purity of product was 97.11%. All impurities meet the requirements of Pharmacopoeia. The present application is a simpler, more economical and more efficient synthesis method, and is suitable for industrial production.
    Type: Application
    Filed: April 20, 2023
    Publication date: August 17, 2023
    Inventors: Rener CHEN, Xiuwen ZHONG, Youchun HUANG, Lei ZHANG, Wenteng CHEN, Yongping YU
  • Publication number: 20220356156
    Abstract: The present application provides the preparation and use of a 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride. According to the present application, a 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride is directly synthesized by a one-step reaction, and the compound includes a pharmaceutically acceptable salt thereof. 3,4-dihydroxyl-N-(1?-benzyl-2?-hydroxyethyl)-2-methyl pyridine chloride has been proved to have a good antiparkinsonian activity by animal tests, and it is a class of novel antiparkinsonian drug candidates.
    Type: Application
    Filed: June 26, 2022
    Publication date: November 10, 2022
    Inventors: Yongping YU, Robert Charles Hider, Xin YUAN, Feng HAN, Wenteng CHEN, Guolin ZHANG, Zudong LIU, Yu ZHANG
  • Patent number: 9371292
    Abstract: Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: June 21, 2016
    Assignees: SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD., ZHEJIANG UNIVERSITY
    Inventors: Guangxin Xia, Jingkang Shen, Yongping Yu, Wenteng Chen, Chunchun Zhang, Yu Hao, Jing Zhang, Bojun Li, Xuejun Liu
  • Publication number: 20140206687
    Abstract: Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity.
    Type: Application
    Filed: July 27, 2012
    Publication date: July 24, 2014
    Applicants: ZHEJIANG UNIVERSITY, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.
    Inventors: Guangxin Xia, Jingkang Shen, Yongping Yu, Wenteng Chen, Chunchun Zhang, Yu Hao, Jing Zhang, Bojun Li, Xuejun Liu